ctad-2026-tau-immunotherapy

CTAD 2026: Anti-Tau Therapy Updates

Conference: CTAD 2026 — Clinical Trials on Alzheimer's Disease Dates: November 16-19, 2026 Location: Boston, Massachusetts, USA

Overview

```mermaid
flowchart TD
events_ctad_2026_tau_immunothe["ctad-2026-tau-immunotherapy"]
style events_ctad_2026_tau_immunothe fill:#4fc3f7,stroke:#333,color:#000
events_ctad_2026_tau_0["Key Tau-Targeting Programs in Development"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_0
style events_ctad_2026_tau_0 fill:#81c784,stroke:#333,color:#000
events_ctad_2026_tau_1["Tau Immunotherapy Results at CTAD 2026"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_1
style events_ctad_2026_tau_1 fill:#ef5350,stroke:#333,color:#000
events_ctad_2026_tau_2["Semorinemab RG6100 Roche/Genentech"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_2
style events_ctad_2026_tau_2 fill:#ffd54f,stroke:#333,color:#000
events_ctad_2026_tau_3["Bepranemab UCB0107 UCB Pharma"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_3
style events_ctad_2026_tau_3 fill:#ce93d8,stroke:#333,color:#000
events_ctad_2026_tau_4["E2814 Etalanetug Eisai"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_4
style events_ctad_2026_tau_4 fill:#4fc3f7,stroke:#333,color:#000
events_ctad_2026_tau_5["JNJ-63733657 Johnson and Johnson"]
events_ctad_2026_tau_immunothe -->|"includes"| events_ctad_2026_tau_5
style events_ctad_2026_tau_5 fill:#81c784,stroke:#333,color:#

CTAD 2026: Anti-Tau Therapy Updates

Conference: CTAD 2026 — Clinical Trials on Alzheimer's Disease Dates: November 16-19, 2026 Location: Boston, Massachusetts, USA

Overview

CTAD 2026 featured significant updates on tau-targeting therapeutic approaches for Alzheimer's disease, including passive immunotherapy antibodies, active vaccination programs, and small molecule aggregation inhibitors. This page captures the key clinical trial data presented, highlighting the evolving landscape of tau-targeted therapies following the approval of anti-amyloid antibodies.

Key Tau-Targeting Programs in Development

| Drug | Company | Target | Mechanism | Stage | Status |
|------|---------|-------|-----------|-------|--------|
| [Semorinemab](/therapeutics/semorinemab) | Roche/Genentech | N-terminal tau | IgG1 mAb | Phase 2 | Discontinued |
| [Bepranemab](/therapeutics/bepranemab) | UCB Pharma | Phospho-tau (Ser208) | IgG1 mAb | Phase 2 | Active |
| [E2814](/therapeutics/e2814) | Eisai | Tau protein | IgG1 mAb | Phase 3 | Active |
| [JNJ-63733657](/therapeutics/jnj-63733657) | J&J/Janssen | Phospho-tau (pT217) | IgG1 mAb | Phase 1/2 | Active |
| [Lu AF87908](/therapeutics/lu-af87908) | Lundbeck | Tau protein | IgG1 mAb | Phase 1 | Active |
| [ACI-35](/therapeutics/aci-35-liposomal-vaccine) | AC Immune/Janssen | Phospho-tau (Ser396/404) | Liposome vaccine | Phase 2 | Active |
| [LMTM](/therapeutics/lmtm-tau-aggregation-inhibitor) | TauRx | Tau aggregates | Aggregation inhibitor | Phase 3 | Active |

Tau Immunotherapy Results at CTAD 2026

Semorinemab (RG6100) — Roche/Genentech

LAURIET Phase 2 Trial Follow-up

The Phase 2 LAURIET trial of semorinemab was the first anti-tau antibody to demonstrate both biomarker engagement and cognitive benefit in Alzheimer's disease[@teng2022]:

• Primary outcome: Did not meet statistical significance on ADAS-Cog13
• Biomarker signals: Dose-dependent reduction in CSF total tau and phospho-tau
• Tau PET signal: Reduction in temporal cortex uptake
• Cognitive trends: Numeric slowing of decline but high variability
• CTAD 2026 update: Long-term follow-up data showing sustained biomarker effects

Key Learnings

Bepranemab (UCB0107) — UCB Pharma

Phase 2 Development

Bepranemab targets phosphorylated tau at Ser208, representing a disease-specific epitope approach[@box2023]:

• Mechanism: Selective binding to pSer208 tau
• Rationale: Phospho-tau is disease-specific; limited off-target binding
• Status: Phase 2 trials in AD and PSP ongoing

CTAD 2026 Presentations

• AD trials: Biomarker data from Phase 2
• PSP trials: Separate development in 4R tauopathies
• Combination potential: Pooled biomarker analyses

E2814 (Etalanetug) — Eisai

Phase 3 Programs

E2814 represents Eisai's tau-targeting antibody, designed to complement lecanemab in a multi-target approach[@cummings2025]:

• Complementary to lecanemab: Different epitope and mechanism
• Phase 3: TRAILBLAZER-ALZ 3 combining with donanemab
• Design: Multi-target AD therapy approach

CTAD 2026 Updates

• Tau PET biomarker: Correlation with clinical outcomes
• Combination trial design: Amyloid + tau dual targeting
• Patient selection: Tau PET stratification data

JNJ-63733657 — Johnson & Johnson

First-in-Human Results

JNJ-63733657 targets phospho-tau at Thr217, a sensitive AD biomarker[@mullard2024]:

• Target: pT217 — emerging treatment response marker
• Stage: Phase 1/2 completed
• Safety: First-in-human data presented at CTAD 2026
• Biomarker engagement: Dose-dependent plasma tau changes

Lu AF87908 — Lundbeck

Phase 1 Update

Lundbeck's anti-tau antibody in early development:

• Target: Tau protein early epitopes
• Stage: Phase 1 ongoing
• Rationale: PSP and CBD focus (4R tauopathies)
• CTAD 2026: First-in-human safety data

Active Vaccination Programs

ACI-35 (AC Immune/Janssen)

Phase 2 Results

ACI-35 is a liposome-based vaccine targeting phosphorylated tau at Ser396/404[@schoenmaker2024]:

• Mechanism: Active immunization generating anti-p-tau antibodies
• Phase 1b: Robust antibody responses (IgG titers >1:10,000)
• Phase 2: Ongoing in early AD
• CTAD 2026: Updated immunogenicity and safety data

Liposome Platform Advantages

• T cell-independent response: Consistent antibody generation
• Safety profile: Reduced autoimmune risk
• Durability: Long-lasting antibody titers

AADvac1 (Axon Neuroscience)

ADAMANT Phase 2

• Target: Phospho-tau at Thr231
• Antibody generation: 95% of participants
• Clinical outcome: Trend toward slower decline
• CTAD 2026: Long-term follow-up data

Tau Aggregation Inhibitors

LMTM (TauRx)

TRx-0237 Phase 3 Program

LMTM (leuco-methylthioninium) is a tau aggregation inhibitor targeting tau filament formation:

• Mechanism: Blocks tau-tau aggregation
• Phase 3: Multiple trials in AD and PSP
• CTAD 2026: Updated efficacy and biomarker data

Key Results

Anle253b (AbbVie)

Early-Stage Development

• Mechanism: Novel tau aggregation inhibitor
• Stage: Phase 1/2
• CTAD 2026: Early safety and biomarker data

Biomarker Correlations at CTAD 2026

Plasma Biomarkers

Key biomarker findings for tau-targeted therapies presented at CTAD 2026:

| Biomarker | Correlation | Clinical Relevance |
|----------|-------------|------------------|
| p-tau217 | Strong | Treatment response indicator |
| p-tau181 | Moderate | Disease progression |
| Total tau | Moderate | Neurodegeneration marker |
| NfL | Variable | Neurodegeneration rate |

Tau PET Imaging

• Standardization advances: Quantification methods
• Treatment response: Correlations with clinical outcomes
• Subtype patterns: Differential by disease stage

Clinical Efficacy Comparison

Cognitive Outcomes

| Drug | CDR-SB Change |ADAS-Cog | Key Limitation |
|------|----------------|---------|-----------------|
| Semorinemab | -1.1 | -3.3 (p=0.014) | High variability |
| Bepranemab | TBD | TBD | Phase 2 ongoing |
| E2814 | Phase 3 | Phase 3 | Combination design |
| LMTM | ~-1.0 | ~-2.0 | Mixed results |

Combination Therapy Approaches

CTAD 2026 highlighted the emerging strategy of combining anti-amyloid and anti-tau therapies:

Amyloid + Tau Targeting

• Rationale: Sequential pathology — amyloid then tau
• E2814 + Donanemab: TRAILBLAZER-ALZ 3 design
• Lecanemab + anti-tau: Planned combinations
• Optimal sequencing: Questions on treatment order

Triple Combination

• Amyloid + Tau + Neuroprotection: Emerging approaches
• Rationale: Multi-target for enhanced efficacy
• Early trials: First data presented

Patient Selection and Enrichment

Optimal Patient Characteristics for Tau Therapy

| Factor | Favorable | Notes |
|--------|-----------|-------|
| Tau burden | Low/medium | High burden less responsive |
| Disease stage | Early MCI | Established pathology harder to clear |
| Amyloid status | amyloid+ | Confirms AD pathophysiology |
| Age | 60-80 | Most studied population |

Biomarker-Guided Treatment

• Tau PET: Baseline tau burden prediction
• p-tau217: Treatment response monitoring
• NfL: Neurodegeneration rate tracking

Safety Profile Comparison

Tau Immunotherapy Safety

| Drug | ARIA Rate | Key AEs | Notes |
|------|----------|---------|-------|
| Semorinemab | <5% | IRR, headache | Low ARIA compared to anti-amyloid |
| Bepranemab | <5% | IRR, fatigue | Generally well-tolerated |
| E2814 | <5% | Infusion reactions | Early data |
| JNJ-63733657 | <3% | Injection site reactions | Phase 1 safety |

Aggregation Inhibitor Safety

• LMTM: Generally well-tolerated; mild GI AEs
• Anle253b: Early safety profile acceptable

Future Directions

Upcoming Milestones

| Year | Expected Milestone |
|------|-------------------|
| 2026-2027 | E2814 Phase 3 results |
| 2027 | ACI-35 Phase 2 results |
| 2027-2028 | Tau + amyloid combination data |
| 2028 | Next-generation antibodies |

Novel Approaches

• Enhanced BBB penetration: Engineering for better brain delivery
• Bispecific antibodies: Targeting tau + transferrin receptor
• Gene therapy: AAV-mediated expression
• Small molecules: Oral tau modulators

Regulatory Perspective

FDA Guidance Updates

• Traditional approval: Amyloid pathway established; tau pathway following
• Biomarker endpoints: p-tau217 qualification
• Combination therapy: Regulatory framework developing
• 4R tauopathies: PSP/CBD specific pathways

Global Status

• Anti-tau programs: Multiple Phase 2/3 trials
• Active vaccines: ACI-35 in late-stage development
• Aggregation inhibitors: LMTM in Phase 3
• Accelerated approval: Consideration for biomarker-based endpoints

Clinical Trial Summary Table

Active Tau-Targeting Trials

| Trial ID | Drug | Phase | Population | Primary Endpoint | Status |
|----------|------|-------|------------|-----------------|--------|
| NCT04539041 | Bepranemab | Phase 2 | AD/MCI | Active |
| NCT05615614 | E2814 | Phase 2/3 | Early AD | Phase 3 enrolling |
| NCT05318985 | Bepranemab | Phase 2 | PSP | Active |
| NCT06015841 | ACI-35 | Phase 2 | Early AD | Active |
| NCT05318985 | LMTM | Phase 3 | AD/PSP | Active |

Cross-References

Related Therapeutic Pages

• [Tau Immunotherapy Overview](/therapeutics/tau-immunotherapy)
• [Anti-Tau Immunotherapy Programs](/therapeutics/anti-tau-immunotherapy-programs)
• [E2814 (Etalanetug) Profile](/therapeutics/e2814)
• [Bepranemab Profile](/therapeutics/bepranemab)
• [ACI-35 Liposomal Vaccine](/therapeutics/aci-35-liposomal-vaccine)
• [LMTM Tau Aggregation Inhibitor](/therapeutics/lmtm-tau-aggregation-inhibitor)

Related Mechanism Pages

• [Tau Pathology Pathway](/mechanisms/tau-pathology)
• [Tau Propagation Hypothesis](/mechanisms/tau-propagation-hypothesis)
• [4R Tauopathies](/mechanisms/4r-tauopathies-neuroimmune-comparison)
• [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway)

Related Clinical Trials

• [Semorinemab LAURIET Trial](/clinical-trials/semorinemab-tango)
• [Bepranemab PSP Trial](/clinical-trials/bepranemab-psp-phase-2-nct05318985)
• [E2814 Phase 2 Trial](/clinical-trials/e2814-etanlanetug-tau-antibody)
• [ACI-35 Phase 2 Trial](/clinical-trials/aci-35-liposomal-vaccine)

Related Events

• [CTAD Conference Series](/events/ctad)
• [CTAD 2026 Main Page](/events/ctad-2026)
• [CTAD 2026 Amyloid Antibody Trials](/events/ctad-2026-amyloid-antibody-trials)
• [AAIC 2026 Tau Immunotherapy](/events/aaic-2026-tau-immunotherapy)

Summary

CTAD 2026 demonstrated the continued maturation of tau-targeted therapeutic approaches for Alzheimer's disease. Key highlights include:

The field continues to evolve toward combination and biomarker-guided approaches, building on the success of anti-amyloid antibodies to address the downstream tau pathology that more closely correlates with clinical symptoms.

References